Multicenter clinical trial of Percutaneous Peptide Immunization for malignant melanoma patients

Multicenter clinical trial of Percutaneous Peptide Immunization for malignant melanoma patients - Multicenter clinical trial of Percutaneous Peptide Immunization for malignant melanoma patients

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000005706

Enrollment

Registered

2011-06-10

Start date

2003-06-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

malignant melanoma

Interventions

Percutaneous immunization

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients with malignant melanoma. HLA-A0201 or HLA-A2402 positive patient.

Exclusion criteria

Exclusion criteria: Not received chemo therapy within a month. No big metastatic lesion in the liver or in the brain. Not pregnant. Not receiving immunosuppressive agent. No eczematous lesion on the skin. No hepatitis. No collagen disease.

Design outcomes

Primary

Measure	Time frame
Overall survival by status of tumor specific cytotoxic T cell induction	—

Secondary

Measure	Time frame
Induction rate of tumor specific cytotoxic T cell. Tumor regression Adverse events	—

Countries

Japan

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026